COMPANION MEETINGS

Association for Molecular Pathology




  Sunday, March 8, 2009 — 7:30 PM, Convention Center BRC  
  • Getting the Right Treatment: Genetic and Epigenetic Changes in Tissue
  Moderator: Timothy J. O’Leary, Department of Veterans Affairs, Washington, DC
  Disclosure: In accordance with ACCME guidelines regarding disclosure, the USCAP policy requires that faculty members who have a significant financial or other relationship with a commercial company, entity, or service (which will be discussed in this Symposium) must disclose this to attendees. The Academy also requires that speakers disclose any products that are not labeled for the use under discussion. Margaret Gulley is a consultant for Qiagen. The other speakers listed below have indicated they have nothing to disclose.




Click the button above to add this event to your Itinerary Planner...



7:30  Introduction - Timothy J. O'Leary, Department of Veterans Affairs, Washington, DC
7:45  Clinical and Pathological Significance of Epigenomic Changes in Colorectal Cancer - Shuji Ogino, Brigham & Women's Hospital, Dana Farber Cancer Institute & Harvard Medical School, Boston, MA
8:20  Targeted Therapy of Melanoma: Kinases, Inhibitors and Molecular Correlates of Response - D. A. Jones, Anderson Cancer Center, Houston, TX
8:55  Molecular Pathology of AML - Margaret Gulley, University of North Carolina, Chapel Hill, NC
Topics were selected by Timothy O’Leary on the basis of email dialogue with members of the Association for Molecular Pathology who are also members of the USCAP, initiated by a posting in the CHAMP listserve, and considering topics previously discussed in this companion meeting. The topics provide updates for practicing anatomic pathologists on advances in molecular pathology that have implications for the selection of targeted therapies on several different tumor types. The objective is to provide updates on the molecular pathology of colorectal cancer, malignant melanoma, and acute myeloblastic leukemia that have implications for the selection of targeted therapies.